Ads
related to: phentermine 37.5 mg prescription
Search results
Results From The WOW.Com Content Network
[6] [6] Peak concentrations of phentermine are reached 6 hours following oral administration of a dose of 15 mg. [6] The steady-state levels of phentermine with continuous administration have been found to be around 200 ng/mL in clinical studies. [6] The oral bioavailability of phentermine is not affected by intake of a high-fat meal. [6]
Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.
Fenfluramine as a single drug was first introduced in the 1970s, but was not popular because it only temporarily reduced weight. [1] A 1984 study found a weight loss of 7.5 kg on average in 24 weeks, as compared to 4.4 kg under placebo. [4]
Phenmetrazine has been used as an appetite suppressant for purposes of weight loss. [2] It was used therapeutically for this indication at a dosage of 25 mg two or three times per day (or 50–75 mg/day total) in adults. [2]
While there is a lack of randomized controlled trials evaluating the use of triamterene in the treatment of Ménière's disease, the typical treatment is 37.5 mg of triamterene with 25 mg of hydrochlorothiazide 1–2 capsules daily. [25] [26] This recommendation was given a Strength of Recommendation Taxonomy (SORT) grade of C. [citation needed]
Fenfluramine is indicated for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome in people age two and older. [3] [7] [4]Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. [7]
Ads
related to: phentermine 37.5 mg prescription